Phathom Pharmaceuticals (PHAT) 25th Annual Needham Virtual Healthcare Conference summary

Company strategy and market focus

• VOQUEZNA, a next-generation PCAB for gastroesophageal reflux, launched late 2023 and targets patients unresponsive to PPIs or H2 blockers.

• Strategic shift in 2025 prioritized gastroenterology prescribers, now accounting for over 70% of sales calls and prescriptions.

• Growth is driven by focusing on high-need GI patients, with plans to expand into primary care as adoption grows.

• Revenue guidance for 2026 is $320–$345 million, with a goal of achieving operating profitability in Q3 and Q4 2026 and positive cash flow in 2027.

• Peak revenue potential is estimated at $1 billion from GI specialists and another $1 billion from primary care, with current focus on GI and gradual expansion to primary care by 2028–2029.

Sales execution and prescription trends

• Sales force of 300 reps is heavily focused on GI, with ongoing optimization of marketing spend and paused DTC campaigns.

• Prescription growth follows a pattern: initial adoption by GI for severe cases, then expansion to broader patient groups as confidence builds.

• Seasonality impacts Q1 prescription volumes due to insurance plan resets, but robust recovery is seen in March, mirroring prior years.

• Over 20% penetration in PPI-to-VOQUEZNA switches among top 300 prescribers, supporting long-term growth targets.

• Expansion into primary care will be ROI-driven, with current efforts targeting top decile primary care offices and future broader push as metrics improve.

Financial position and capital structure

• Recent equity raise and debt restructuring resulted in a sustainable, transparent, and cost-effective capital structure.

• Term debt stands at $175 million with a 9.85% interest rate, maturing in February 2029; cash on hand at the start of the year was about $190 million.

• Royalty financing remains unchanged at $275 million, with manageable cash flow requirements.

• Liquidity is sufficient to meet obligations through 2025 and beyond, supporting ongoing investment in business growth.